Investor Presentaiton
Investor presentation
ADA 2019
Slide 31
REFLECT demonstrated lower hypoglycaemia risk-profile of
TresibaⓇ as well as increased quality of life vs other basal insulins
Significant reduction of all types of
hypoglycaemic events
Patients' treatment satisfaction and quality of life
Observed treatment difference at 12 months
follow-up from baseline with TresibaⓇ
Baseline
12 months follow-up
%
50
T1D any hypoglycaemic episodes
0.80 [0.75;0.87]*
T2D any hypoglycaemic episodes
0.49 [0.41;0.60]*
40
T1D non-severe hyp. episodes
T2D non-severe hyp. episodes
T1D nocturnal hyp. episodes
T2D nocturnal hyp. episodes
T1D ADA-defined severe hyp.
episodes
T2D ADA-defined severe hyp.
episodes
0.81 [0.75;0.87]*
0.49 [0.41;0.59]*
0.58 [0.49;0.70]*
0.36 [0.21;0.61]*
0.41 [0.23;0.73]+
NA
DTSQ-s total score
10
29.9
30.0
30
26.0
25.7
20
0.125
0.25
0.5
Favours degludec
*p<0.001, p=0.003
1
2
Rate ratio
(follow-up/baseline)
Negative binomial regression model with log link and log of exposure as offset
T
4
Favours previous
basal insulin
ADA: American Diabetes Association; NA: not available; T1D: type 1 diabetes; T2D: type 2 diabetes;
hyp. hypoglycaemic
8
T1D
T2D
Percentages are based on the number of patients who responded that they used the specific
flexibility option one or more times and calculated based on number of patients with evaluable data
DTSQ: Diabetes Treatment Satisfaction Questionnaire; QoL: quality of life; SF: Short Form; T1D:
type 1 diabetes; T2D: type 2 diabetesView entire presentation